USPTO Examiner MCKNIGHT CIARA A - Art Unit 1656

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19071345PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOFMarch 2025October 2025Allow810YesNo
19026516ERGOTHIONEINE-PRODUCING ENGINEERED BACTERIA AND CONSTRUCTION METHOD AND USE THEREOFJanuary 2025October 2025Allow911YesNo
18977534STRAINS AND METHODS FOR THE CONTINUOUS PRODUCTION OF PRODUCTS BY GAS FERMENTATIONDecember 2024March 2026Abandon1511NoNo
18655606ENGINEERED HUMAN EXTRACELLULAR DNASE ENZYMES FOR DRUG CANDIDATE SELECTIONMay 2024March 2026Abandon2201NoNo
18276657BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS AND USE THEREOFAugust 2023October 2025Allow2620YesNo
18325252NOVEL ASPERGILLUS ORYZAE STRAIN AND USE THEREOFMay 2023December 2024Allow1920YesNo
18037299METHOD AND DRUG FOR INCREASING BDNF LEVELMay 2023March 2026Abandon3401NoNo
18317144METHOD OF ENZYMATICALLY PREPARING N-3 POLYUNSATURATED FATTY ACID DIACYLGLYCEROLMay 2023August 2024Allow1520YesNo
18300194MOISTURE INDUCED BIOLUMINESCENT COMPOSITION AND METHODS FOR MANUFACTURING THEREOFApril 2023September 2025Abandon2931NoNo
18189272TRANSFORMANT FOR PRODUCING DODECANEDIOIC ACID AND METHOD FOR PRODUCING DODECANEDIOIC ACIDMarch 2023January 2025Allow2230NoNo
18180507NOVEL METHOD FOR PREPARING POLY(3-HYDROXYBUTYRATE-CO-HYDROXYBUTYRATE)March 2023July 2025Allow2831YesNo
18117082ENGINEERED ENZYMES AND BIOPRODUCTION OF BAKUCHIOLMarch 2023September 2024Allow1811NoNo
18161794METHODS FOR PRODUCTION OF AMYELOIS TRANSITELLA PHEROMONE PRECURSORJanuary 2023February 2025Abandon2411NoNo
18068418PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOFDecember 2022June 2024Allow1811NoNo
18068218PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOFDecember 2022June 2024Allow1811NoNo
18068443PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOFDecember 2022July 2024Allow1911NoNo
18068327PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOFDecember 2022July 2024Allow1911NoNo
18066960PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOFDecember 2022June 2024Allow1811YesNo
18064886PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOFDecember 2022May 2024Allow1711NoNo
18060193GENE EDITING SYSTEM FOR EDITING THE ARYLSULFATASE A (ARSA) GENENovember 2022July 2024Allow2011NoNo
18071024PRODUCTION OF FUNGAL BIOMASS FROM SIMPLE CARBON SOURCESNovember 2022March 2025Abandon2820NoNo
18070554HIGHER PERFORMANCE PROTEASES FOR SCARLESS PEPTIDE TAG REMOVALNovember 2022February 2026Abandon3901NoNo
17907278METHOD FOR PRODUCING PHA USING SEA WATERSeptember 2022February 2026Abandon4010NoNo
17951849CHIMERIC POLYPEPTIDES HAVING TARGETED BINDING SPECIFICITYSeptember 2022March 2026Allow4211NoNo
17789977RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USEJune 2022October 2025Abandon4011NoNo
17787955CHIMERIC DNA POLYMERASE AND APPLICATION THEREOFJune 2022March 2026Allow4511YesNo
17776490MODIFIED KLENOW FRAGMENT AND APPLICATION THEREOFMay 2022September 2025Allow4111YesNo
17736396METHOD FOR PRODUCING BONE GELATINE, AND PRODUCED BONE GELATINEMay 2022April 2025Abandon3501NoNo
17773667MICROBIAL DETECTION PLATFORMMay 2022August 2025Abandon4001NoNo
17773403MEDICAL COMPOSITIONS AND THEIR USE IN TREATING PANCREATIC CANCERApril 2022August 2025Abandon3901NoNo
17769630METHOD FOR PRODUCING FUSION PROTEIN OF SERUM ALBUMIN AND GROWTH HORMONEApril 2022December 2025Allow4411YesNo
17767764BIOSYNTHESIS OF CANNABINOIDS FROM CANNABIGEROLIC ACID USING NOVEL CANNABINOID SYNTHASESApril 2022August 2025Allow4011YesNo
17767033SARS-COV-2 RECOMBINANT N PROTEIN, AND PREPARATION METHOD AND PURIFICATION METHOD THEREFORApril 2022March 2026Abandon4721NoNo
17764354PEPTIDE PURIFICATION FORMULATIONS AND METHODSMarch 2022February 2026Allow4721NoNo
17764127THERAPEUTIC EFFICACY BY PULMONARY DELIVERY OF LIVE ATTENUATED MYCOBACTERIAMarch 2022December 2025Allow4520YesNo
17640307DELIVERY VEHICLE FOR IN SITU DELIVERING OF PHARMACEUTICAL AGENTSMarch 2022August 2025Abandon4111NoNo
17633517METHOD FOR CULTURING DERMAL PAPILLA CELLSFebruary 2022February 2025Abandon3601NoNo
17632819NUCLEIC ACIDS, PROTEINS AND PROCESSES FOR PRODUCING AMIDESFebruary 2022December 2024Abandon3501NoNo
17631162METHODS AND KITS FOR IDENTIFYING THROMBUS ORIGIN AND OPTIMIZING POST-ISCHEMIC EVENT TREATMENTJanuary 2022September 2025Allow4411YesNo
17587253Compositions and Methods for Treating Pathological Calcification and OssificationJanuary 2022November 2025Allow4611YesNo
17582548ANTIGENIC POLYPEPTIDES AND METHODS OF USE THEREOFJanuary 2022January 2025Abandon3601NoNo
17626822METHOD FOR THE PRODUCTION OF AN ENZYMATIC COMPOSITION COMPRISING A RECOMBINANT ENDOPEPTIDASEJanuary 2022October 2025Abandon4521NoNo
17626665METHOD FOR EVALUATING ANTIBIOTIC SUSCEPTIBILITYJanuary 2022March 2025Abandon3810NoNo
176265613' UTR CRISPR-DCAS 13 ENGINEERING SYSTEM AND METHODS OF USING SAMEJanuary 2022July 2025Allow4221YesNo
17625727A recombinant protein produced from cholinesterase gene derived from Pseudomonas aeruginosa and the composition comprising the same for treating or preventing a neurological diseaseJanuary 2022February 2025Allow3810NoNo
17597306SERPIN PRODUCTIONDecember 2021February 2026Allow5041YesNo
17597012NOVEL LACTIC ACID BACTERIUM DERIVED FROM AMUR CORK LIVING IN SHIRAKAMI MOUNTAINSDecember 2021December 2024Abandon3601NoNo
17618938METHODS OF PROTEIN EXTRACTION AND DOWNSTREAM PROCESSING OF EUGLENADecember 2021February 2025Abandon3810NoNo
17606263COLANIC ACID PRODUCTION USING MUTANT E. COLIDecember 2021June 2025Abandon4420NoNo
17614648ASSISTANT AGENT FOR ASSISTING INTRODUCTION INTO LIVING BODY AND METHOD OF UTILIZING THE SAMENovember 2021November 2025Abandon4701NoNo
17611972IMPROVED DELIVERY OF GENE THERAPY VECTORS TO RETINAL CELLS USING A GLYCOSIDE HYDROLASE ENZYMENovember 2021September 2025Abandon4621NoNo
17609113PROBIOTICS FOR MENTAL HEALTHNovember 2021January 2025Abandon3810NoNo
17607371METHOD FOR ASYMMETRICALLY PREPARING L-PHOSPHINOTHRICIN BY OXIDATION-REDUCTION REACTION THROUGH BIOLOGICAL MULTI-ENZYME COUPLINGOctober 2021September 2024Allow3511YesNo
17605120ENGINEERED TRANS-ENOYL COA REDUCTASE AND METHODS OF MAKING AND USINGOctober 2021February 2026Abandon5221NoNo
17605196ENGINEERED MICROORGANISMS AND METHODS FOR IMPROVED ALDEHYDE DEHYDROGENASE ACTIVITYOctober 2021November 2025Allow4921NoNo
17604417CIRCULARLY PERMUTATED HALOALKANE TRANSFERASE FUSION MOLECULESOctober 2021March 2025Allow4111YesNo
17601802USING SYNTHETIC LIXIVIANT BIOLOGY FOR THE RECOVERY OF PRECIOUS AND TOXIC METALS FROM ANTHROPOGENIC SOURCESOctober 2021July 2025Allow4511YesNo
17601197IMPROVEMENT OF AFFINITY CHROMATOGRAPHY OF IMMUNOGLOBULINS BY USING PRE-CAPTURE FLOCCULATIONOctober 2021December 2025Allow5020YesYes
17600927FUNGAL EXTRACTS AND FLAVOR COMBINATIONS THEREOFOctober 2021February 2026Abandon5221NoNo
17601052NOVEL NUCLEIC ACID MODIFIERSOctober 2021August 2025Abandon4701NoNo
17600276PROCESS FOR THE PURIFICATION OF RECOMBINANT POLYPEPTIDESSeptember 2021February 2026Abandon5331NoNo
17442675Amylase EnzymesSeptember 2021December 2025Allow5021NoNo
17435709Artificial Fusion of Dehydratase Enzymes to Improve Production of Fatty AcidsSeptember 2021September 2025Allow4911YesNo
17435695PRODUCTION OF CANNABINOIDS USING GENETICALLY ENGINEERED PHOTOSYNTHETIC MICROORGANISMSSeptember 2021October 2024Abandon3701NoNo
17430013LACHNOSPIRACEAE BACTERIUM ND2006 CAS12A MUTANT GENES AND POLYPEPTIDES ENCODED BY SAMEAugust 2021November 2024Allow3921NoNo
17429493METHOD FOR CONTINUOUS PRODUCTION OF RECOMBINANT GLP-1 PEPTIDE BY BACTERIAAugust 2021August 2024Allow3620NoNo
17427974ENGINEERED HUMAN EXTRACELLULAR DNASE ENZYMES FOR DRUG CANDIDATE SELECTIONAugust 2021September 2024Abandon3801NoNo
17389026ENHANCEMENT OF HYDRATION AND IMPROVEMENT IN GUT HEALTH THROUGH CLOACAL DELIVERY OF PRODUCTSJuly 2021December 2025Allow5320NoNo
17372406NOVEL NUCLEIC ACID MODIFIERSJuly 2021March 2026Abandon5621NoNo
17421243MODIFIED FIBROINJuly 2021March 2025Allow4421YesNo
17418319LIQUID COMPOSITION COMPRISED OF A MICELLAR CASEIN CONCENTRATEJune 2021August 2024Abandon3701NoNo
17416143Method for Filtering FibrinogenJune 2021October 2025Allow5230YesNo
17311771COMPOSITION FOR PROMOTING GROWTH OF EFFECTIVE MICROORGANISM AND CONTROLLING PLANT DISEASE USING PREBIOTICS, AND USE THEREOFJune 2021June 2024Allow3620NoNo
17296559METHOD FOR PREPARATION OF PRIMARY AMINE COMPOUNDSMay 2021February 2025Abandon4520YesNo
17327586PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOFMay 2021May 2024Allow3511YesNo
17293230MICROBIAL CELLS AND METHODS FOR PRODUCING CANNABINOIDSMay 2021July 2024Abandon3810NoNo
17242116Crystal Structure of a Replication Protein encoded by a Plasmid isolated from a Multiple Sclerosis PatientApril 2021November 2024Allow4311YesNo
17250769A DOUBLE PEPTIDE TAG COMBINING REVERSIBILITY AND FLEXIBLE FUNCTIONALIZATIONMarch 2021June 2025Abandon5221NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MCKNIGHT, CIARA A.

Strategic Value of Filing an Appeal

Total Appeal Filings
1
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
1
(100.0%)
Filing Benefit Percentile
0.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MCKNIGHT, CIARA A - Prosecution Strategy Guide

Executive Summary

Examiner MCKNIGHT, CIARA A works in Art Unit 1656 and has examined 33 patent applications in our dataset. With an allowance rate of 48.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.

Allowance Patterns

Examiner MCKNIGHT, CIARA A's allowance rate of 48.5% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MCKNIGHT, CIARA A receive 1.48 office actions before reaching final disposition. This places the examiner in the 25% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MCKNIGHT, CIARA A is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +63.6% benefit to allowance rate for applications examined by MCKNIGHT, CIARA A. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 71% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 53.3% of cases where such amendments are filed. This entry rate is in the 79% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 12.5% of allowed cases (in the 90% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.